ARTICLE | Clinical News
ALKS 9070: Phase III started
January 2, 2012 8:00 AM UTC
Alkermes began a double-blind, placebo-controlled Phase III trial evaluating 300 and 600 mg once-monthly intramuscular ALKS 9070 for 12 weeks in about 690 patients experiencing acute exacerbation of s...